Healthcare Review: Dynavax Technologies, Apricus Biosciences, ACADIA Pharmaceuticals, Celldex Therapeutics, Avanir Pharmaceuticals Print E-mail
By Staff and Wire Reports   
Monday, 10 June 2013 13:38
US stocks edged higher in a volatile session on Monday after Standard & Poor's raised its credit outlook for the United States, but uncertainty about when or if the Federal Reserve might reduce its stimulus efforts limited gains.  Wall Street seesawed between modest gains and losses in the morning session. Technology stocks were among the day's top gainers with Apple and Facebook supporting the Nasdaq.  Following were notable movers at mid day on Monday

Dynavax Technologies Corporation (NASDAQ:DVAX) shares decreased 27.17% to $1.80. The company, on June 10 reported that it recently concluded a meeting with the U.S. Food and Drug Administration (FDA or Agency) regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine. The meeting followed recommendations expressed in November 2012 by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) regarding the size of Dynavax's safety database.     

Apricus Biosciences Inc. (NASDAQ:APRI) shares climbed 12.10% to $2.87. The company on June 10 announced that its marketing application for VitarosĀ®, indicated for the treatment of patients with erectile dysfunction ("ED"), has been approved through the European Decentralized Procedure ("DCP").

Under the DCP, Apricus Bio filed its application for marketing approval designating Netherlands as the Reference Member State ("RMS") on behalf of nine other European Concerned Member States ("CMS") participating in the procedure.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares climbed 10.58% to $18.81. The company, on June 3, announced that Allergan, Inc. (NYSE: AGN) has advanced an additional product candidate as a potential new treatment for glaucoma. The novel small molecule resulted from joint research conducted by the companies under their recently concluded research collaboration focused on new therapies for glaucoma and related ophthalmic conditions.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares increased 4.32% to $15.20. The company released its earnings data on May 2. The company reported ($0.23) earnings per share for the quarter, missing the analysts' consensus estimate of ($0.22) by $0.01. The company had revenue of $2.41 million for the quarter, compared to the consensus estimate of $2.65 million.

Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) shares jumped 4.24% to $3.93. The company on June 5 announced that the U.S. Food and Drug Administration (FDA) has agreed to an expedited development pathway for their next-generation compound, AVP-786, requiring only a limited pre-clinical package as part of the Investigational New Drug (IND) application. Upon completion of these preclinical studies the company intends to proceed directly into human clinical trials.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus